Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Published: Aug 03, 2017

CHESTERBROOK, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced financial results for the quarter ended June 30, 2017 and provided an update on its pipeline of investigational products.

“The second quarter saw continued progress towards our goal of delivering an innovative new option for patients who are at risk of adverse events associated with IV opioids like morphine,” said Maxine Gowen, Ph.D., chief executive officer. “We have now completed our Phase 3 clinical development for OLINVO and successfully completed our pre-NDA meetings with the FDA. In addition, we have refined our commercial strategy to lay the groundwork for a successful commercial launch.

Back to news